These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29718020)

  • 1. Concurrent anticytokine biologics for the management of severe hidradenitis suppurativa: are they safe and effective?
    Naik HB; McGinness A; Shinkai K
    Cutis; 2018 Mar; 101(3):163;164;176. PubMed ID: 29718020
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
    Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
    Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of hidradenitis suppurativa with biologic medications.
    Lee RA; Eisen DB
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
    Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic Treatment for Hidradenitis Suppurativa.
    Flood KS; Porter ML; Kimball AB
    Am J Clin Dermatol; 2019 Oct; 20(5):625-638. PubMed ID: 31140067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
    Holcomb ZE; Porter ML; Kimball AB
    Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to positive latent tuberculosis infection status is low in patients with hidradenitis suppurativa taking biologic medications.
    Ellis A; Khanna U; Galadari A; Fernandez AP
    J Am Acad Dermatol; 2020 Jul; 83(1):246-248. PubMed ID: 31940465
    [No Abstract]   [Full Text] [Related]  

  • 8. Biologic drugs during COVID-19 outbreak.
    Montesu MA; Biondi G; Sotgiu G; Sucato F; Satta R
    Int J Dermatol; 2020 Oct; 59(10):1293. PubMed ID: 32767379
    [No Abstract]   [Full Text] [Related]  

  • 9. Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option.
    Hotz C; Sbidian E; Ingen-Housz-Oro S; Chosidow O; Wolkenstein P
    Acta Derm Venereol; 2019 Nov; 99(12):1170-1171. PubMed ID: 31314122
    [No Abstract]   [Full Text] [Related]  

  • 10. The Association between Hidradenitis Suppurativa and Crohn's Disease: in Search of the Missing Pathogenic Link.
    van der Zee HH; Horvath B; Jemec GBE; Prens EP
    J Invest Dermatol; 2016 Sep; 136(9):1747-1748. PubMed ID: 27542293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa.
    Braunberger TL; Nartker NT; Nicholson CL; Nahhas AF; Parks-Miller A; Hanna Z; Jayaprakash R; Ramesh MS; Rambhatla PV; Hamzavi IH
    Int J Dermatol; 2018 Sep; 57(9):1088-1093. PubMed ID: 29774531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.
    Schuch A; Fischer T; Boehner A; Biedermann T; Volz T
    Acta Derm Venereol; 2018 Jan; 98(1):151-152. PubMed ID: 28902952
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathophysiology of hidradenitis suppurativa: An update.
    Prens E; Deckers I
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S8-11. PubMed ID: 26470623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term therapy with anakinra in hidradenitis suppurativa in three patients.
    André R; Marescassier H; Gabay C; Pittet B; Laffitte E
    Int J Dermatol; 2019 Nov; 58(11):e208-e209. PubMed ID: 31353451
    [No Abstract]   [Full Text] [Related]  

  • 15. Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa.
    Alhusayen R; Shear NH
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S42-6. PubMed ID: 26470615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hidradenitis suppurativa complicated by squamous cell carcinoma: isoscartopic response.
    Caccavale S; Caccavale T; La Montagna M
    Int Wound J; 2017 Dec; 14(6):1397-1398. PubMed ID: 28544759
    [No Abstract]   [Full Text] [Related]  

  • 17. Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry.
    Naik HB; Alhusayen R; Frew J; Guilbault S; Hills NK; Ingram JR; Kudlinski MV; Lowes MA; Marzano AV; Paul M; Villumsen B; Yannuzzi CA
    J Am Acad Dermatol; 2022 Jan; 86(1):249-252. PubMed ID: 34537252
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.
    Tzanetakou V; Kanni T; Giatrakou S; Katoulis A; Papadavid E; Netea MG; Dinarello CA; van der Meer JWM; Rigopoulos D; Giamarellos-Bourboulis EJ
    JAMA Dermatol; 2016 Jan; 152(1):52-59. PubMed ID: 26579854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of biological treatments in patients with hidradenitis suppurativa.
    Martin-Ezquerra G; Masferrer E; Pujol RM
    G Ital Dermatol Venereol; 2017 Aug; 152(4):373-378. PubMed ID: 27982551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic use in hidradenitis suppurativa: patient perspectives and barriers.
    De DR; Shih T; Fixsen D; Brooks B; Hsiao JL; Shi VY
    J Dermatolog Treat; 2022 Nov; 33(7):3060-3062. PubMed ID: 35737883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.